
11 - 50 employees
💊 Pharmaceuticals
🧬 Biotechnology
Pharmaceuticals • Biotechnology
Egetis is an innovative, integrated pharmaceutical company focused on late-stage development and commercialization of treatments for serious diseases with significant unmet medical needs, particularly in the orphan drug segment. The company's lead product candidate is Emcitate (tiratricol) for MCT8 deficiency/Allan‑Herndon‑Dudley syndrome; its pipeline also includes Aladote for acetaminophen (paracetamol) overdose. Headquartered in Stockholm, Sweden, Egetis positions itself around development, regulatory interaction and market access for rare-disease therapeutics.
Selected: 🇺🇸 United States – Remote USA.
Selected: 🆕 Date Added.
🕒 September 5
Field-based Regional Medical Director advancing Egetis Therapeutics’ rare-disease therapy launches. Leading scientific exchange, clinical-trial support, and pediatric specialist engagement.